Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a leading clinical stage immuno-oncology company that is pioneering the development of innovative therapies to treat cancer. The company's research is focused on CD47, a molecule that tumors use to evade the immune system, and aims to block this "do not eat" signal with decoy receptors. By doing so, they hope to unmask tumor cells and make them visible to, and eradicated by, the immune system. Trillium is committed to using the latest scientific advancements to develop new treatments that will help those suffering from cancer.
Trillium Therapeutics Inc.'s ticker is TRIL
The company's shares trade on the TSX stock exchange
They are based in Mississauga, Ontario
There are 11-50 employees working at Trillium Therapeutics Inc.
It is http://www.trilliumtherapeutics.com/
Trillium Therapeutics Inc. is in the Healthcare sector
Trillium Therapeutics Inc. is in the Biotechnology industry
The following five companies are Trillium Therapeutics Inc.'s industry peers: